Tech Company Financing Transactions
Kolltan Pharmaceuticals Funding Round
Kolltan Pharmaceuticals, based in New Haven, scored $60 million in funding from Deerfield Capital, HBM Healthcare Investments and KLP Enterprises.
Transaction Overview
Company Name
Announced On
3/20/2014
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Proceeds Purpose
Kolltan plans to use the proceeds from the Series D financing to advance the Company's lead clinical-stage candidate, KTN3379, into Phase 2 clinical trials in cancer patients suffering from various malignancies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 George St. 530
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Overview
Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerald McMahon
Chief Medical Officer
Ronald Peck
VP - Product Management
Theresa LaVallee
Browse more venture capital transactions:
Prev: 3/20/2014: Upverter venture capital transaction
Next: 3/20/2014: First Stop Health venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs